Filtered library · Theme
Precision biotech & therapeutics theme · 125 dossiers
Dossiers in the Precision biotech & therapeutics theme cluster — 125 names moving on shared catalysts.
All dossiers KYMR Kymera Therapeutics, Inc. fresh LOW Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing,… SYRE Spyre Therapeutics, Inc. fresh LOW Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026,… RVMD Revolution Medicines, Inc. HIGH Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to… ABT Abbott Laboratories MEDIUM De-rating unwind is now largely priced: $82.56 close on 2026-05-11 to $111.25 on 2026-08-14, RSI 72.2, with the 2026-08-11 Google Health/Lingo partnership and Wolfe's 2026-08-13 upgrade to $130 as the newest fuel. Nothing tests the… ADPT Adaptive Biotechnologies Corporation MEDIUM clonoSEQ MRD pure-play inflecting to self-funding growth (MRD rev +53% YoY, profitability turning); June 15 Immune Medicine separation adds a value-unlock leg. But the tape just broke to fresh 52-wk highs (~$22.92) above the $20–22… AKTS Aktis Oncology, Inc. MEDIUM The "coverage is spent" read broke: Wedbush ($35) and BMO ($37) initiated Outperform on 2026-08-19, taking the cohort to five, and the 2026-08-13 Q2 reaffirmed Q1 2027 AKY-1189 data with $517.3M cash. Price did not follow — $24.07 on… ALKS Alkermes plc MEDIUM Legacy CNS base converting into an OX2R sleep franchise; the mechanism was validated by the FDA's 2026-08-05 approval of Takeda's ORZEYFUL, yet ALKS closed 2026-08-21 at $48.33, 12.5% under its $55.22 high. Catalyst-light until the… AMRX Amneal Pharmaceuticals, Inc. MEDIUM Legacy-generics-to-specialty re-rate with both 2026 tests cleared — 2026-07-30 Q2 beat plus a second FY2026 raise, Kashiv closed 2026-08-10 on $350M of term loan and 28.9M Class A shares — but the tape has faded to a 2026-08-21 close of… BMY Bristol-Myers Squibb Co. MEDIUM Legacy-pharma re-rate off the 2026-07-30 guidance reset ($49.0–50.0B sales, $6.75–7.00 adj EPS) is intact, but both attention legs are spent: the AstraZeneca merger was denied 2026-08-05 and the FDA approved ZENBEXUS on 2026-08-13, four… CADL Candel Therapeutics, Inc. MEDIUM Pre-BLA re-rating re-armed: July's round-trip reversed, price reclaimed the June $11.36 high and closed 2026-08-14 at $11.72, 0.7% under the 52-week high, after the 8/13 Q2 print reaffirmed a Q4 2026 prostate BLA and $201.6M cash into Q1… CERT Certara, Inc. MEDIUM Guidance held rather than got cut again: the 2026-08-04 Q2 print reaffirmed FY26 revenue $367-382M and adj EPS $0.31-0.36 despite a revenue miss, and the $6.87 premarket gap round-tripped to an $8.43 close on 08-21. The leg is self-help —… CGEM Cullinan Therapeutics, Inc. MEDIUM CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout… CMPS COMPASS Pathways Plc MEDIUM Clinical binary resolved 2026-07-07; what trades now is regulatory execution — rolling NDA completion guided Q4 2026, H1 2027 launch, $433.3M cash into 2028. The empty calendar just filled: FDA holds a public hearing 2026-09-14 on… CYRX CryoPort, Inc. MEDIUM Q2 (2026-08-06) split the read: revenue $49.0M beat $48.21M and FY26 guide affirmed at $192–196M with adjusted EBITDA crossing to +$0.4M, but commercial CGT growth halved to +9% YoY from +26%. The narrative leg is now the profitability… DYN Dyne Therapeutics, Inc. MEDIUM maturing — nothing company-dated until the ~late-October Q3 print, then the 2027-01-21 PDUFA. ENVA Enova International, Inc. MEDIUM Credit-normalisation plus origination growth still working, but the repricing has stalled: $242.93 on 2026-08-21 is 8.5% under the $265.45 high with RSI 37.6 after a +54.2% three-month run. Two August filings cut funding cost (ABS priced… EOLS Evolus, Inc. fresh MEDIUM Margin-inflection re-rating still paying: Q2 (2026-08-05) printed $84.1M revenue (+21% YoY) and a third straight positive adjusted EBITDA quarter, and price has since marked a new 52-week high at $8.60 (2026-08-21 close $8.39, RSI 77.3).… ETON Eton Pharmaceuticals, Inc. MEDIUM Q2 on 2026-08-13 resolved the binary upward — product sales $37.6M vs $27.1M consensus, FY26 guide to >$145M from >$120M — and four brokers raised targets inside four sessions. Accelerating, but priced into the top of the published targets. EVER EverQuote, Inc. MEDIUM The 2026-08-03 Q2 print resolved the plateau binary bullish: revenue $195.1M (+25% YoY) broke the three-quarter ~$190M band, adjusted EBITDA hit a record $30.1M, and Q3 was guided $198–208M above the $201.6M consensus. The leg is now… GH Guardant Health, Inc. MEDIUM Q2 (7/30) beat and lifted FY26 to $1.340–1.360B, but the second target wave on 8/3–8/4 (Stephens $195, Piper $193, MS $185) again failed to clear Citi's $215 from 7/8. Fundamentals still stepping up while the sell-side ceiling has been… GHRS GH Research PLC MEDIUM Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next… GRND Grindr Inc. MEDIUM Q2 (2026-08-06) resolved the binary bullishly — revenue $138.1M +33% vs $132.4M consensus, FY guide to ~$540M/~$232M EBITDA, three PT raises 2026-08-07 — yet price faded from the ~$18 area on 2026-08-03 to a $16.01 close on 2026-08-14.… ICLR ICON plc MEDIUM Restatement discount still unwinding, now with a balance-sheet leg: on 2026-08-06 ICON priced $2.15B of unsecured notes to repay the bridge facility, all secured term loans and the 5.809% 2027 notes, releasing collateral. The 2026-08-21… IDYA IDEAYA Biosciences, Inc. MEDIUM Approval leg intact but between catalysts: the OptimUM-02 win (HR 0.42, ASCO 2026-06-01) feeds a rolling NDA under FDA RTOR guided complete H2 2026, and Q2 (2026-08-04) showed ~$1.24B cash with runway into 2030. Nothing company-dated until… IKT Inhibikase Therapeutics, Inc. MEDIUM Tape has caught up to the story: after FDA Orphan Drug Designation (2026-07-23) and a Q2 print (2026-08-11) showing 43 sites live across 26 countries and $159.0M cash, IKT closed $2.41 on 2026-08-14, 2.4% off its 52-week high. What is… KNSA Kiniksa Pharmaceuticals International, plc MEDIUM Post-print commercial re-rating still working but no longer fed by new information: the 2026-07-28 FY26 ARCALYST guidance raise to $980–995M and the 07-29/07-30 target ladder are three weeks old, the 08-12 Canaccord fireside produced no… KODK Eastman Kodak Company MEDIUM AM&C inflection is now the entire story: the 2026-08-04 Q2 print put segment revenue at $105M (+40% YoY) and consolidated operational EBITDA at $36M vs $9M, and the ~$9.20 shelf reclaimed on that print has held — the 2026-08-21 close was… LBRX LB Pharmaceuticals Inc fresh MEDIUM Single-asset schizophrenia binary where the sell-side frame flipped above the tape: BMO $54 (2026-08-12), Stifel $53 (08-13), Clear Street $69 (08-20) against a 2026-08-21 close of $47.62 and an $51.5 eight-analyst average. The 2026-08-11… MBX MBX Biosciences, Inc. MEDIUM Single-asset execution story: oPTimize Phase 3 in canvuparatide is guided to start by 2026-09-30 and sites are already screening. Since 2026-08-15 the sell-side re-rated on no new data — consensus $88.36 across 12 analysts (2026-08-23) vs… MGTX MeiraGTx Holdings plc MEDIUM The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 — a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but… MIRM Mirum Pharmaceuticals, Inc. MEDIUM Rare-disease franchise ran to a $125 ATH on FOP data, then cooled ~9% into a confirmed 2026-07-30 Q2 print. Base compounds (Q1 sales +43% YoY, FY guide $660–680M) with FOP PDUFA 2026-09-26 and HDV Phase 3 topline 2H26 stacked ahead — but… MMED MiniMed Group, Inc. MEDIUM Carve-out re-rate extended: MMED closed $20.45 on 2026-08-21, through the prior $20.48 high, after Flex began U.S. shipment integrated with Abbott's Instinct sensor on 2026-08-17 — the last open product item. Reimbursement and integration… NKTR Nektar Therapeutics MEDIUM M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh… OMDA Omada Health, Inc. MEDIUM Post-print re-rating has stalled into a two-week range — $23.89 on 2026-08-21 versus the $26.78 52-week high — after Q2 (2026-08-06) beat at $87.8M revenue (+43%) and lifted the FY guide to $334–340M. The 2026-09-10 first-ever Investor Day… ONC BeOne Medicines Ltd. MEDIUM Q2 print resolved bullish — revenue $1.705B vs $1.591B est., non-GAAP EPS/ADS $3.84 vs $1.44, FY26 guide raised to $6.6–6.8B — but the stock is still 7.9% under the $377.47 52-week high and the 2026-08-06 target wave was increments, not… PTGX Protagonist Therapeutics, Inc. MEDIUM De-risked dual-royalty story accelerating into a binary: icotrokinra (oral IL-23, J&J) already approved and paying 6–10% royalties; rusfertide (PV, Takeda) into a Q3 2026 PDUFA. Stock at a fresh ATH ($143.29, Jul 20) as the PV theme runs —… PVLA Palvella Therapeutics, Inc. MEDIUM First-approved-therapy-for-microcystic-LM story still working: the 2026-08-04 Q2 update reaffirmed rolling-NDA completion in H2 2026 and potential approval H1 2027, and the stock closed $156.13 on 2026-08-14, 1.0% under its 52-week high.… RAPP Rapport Therapeutics, Inc. MEDIUM RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news — the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.… SEPN Septerna, Inc. MEDIUM Re-accelerated on the 2026-08-10 Q2 beat (revenue $26.746M vs $17.875M est; EPS $(0.29) vs $(0.43)) plus SEP-479 Phase 1 PK color: new all-time high $48.19, close $44.50 on 2026-08-14, and five broker target raises in four sessions… SNDX Syndax Pharmaceuticals, Inc. MEDIUM Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance… TRVI Trevi Therapeutics, Inc. MEDIUM Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional… TVTX Travere Therapeutics, Inc. MEDIUM Q2 beat on 2026-08-04 ($169.6M revenue vs $159.6M consensus; FILSPARI US sales +96% YoY to $141.1M) re-opened sell-side headroom — six target raises 08-05→08-10 into a $70–85 band while the 2026-08-14 close of $62.14 sits 1.0% under the… URGN UroGen Pharma Ltd. MEDIUM The 2026-08-05 binary resolved upward: ZUSDURI Q2 net revenue $50.4M (+73% QoQ off the $29.2M Q1 base), total revenue $72.456M vs $63.526M consensus, and a ~22% one-day gap to a $49.00 52-week high. The ramp now runs into an empty calendar… UROY Uranium Royalty Corp. MEDIUM Corporate re-rating from the 2026-07-27 Sweetwater close is now fully priced-in news; RSI(14) 79.9 on 2026-08-21 with no company headline since 2026-08-07, and no combined-company financials exist before the ~2026-09-14 first quarterly… VSTM Verastem, Inc. MEDIUM Post-Q2 the narrative is confirmed and the tape has flattened: $6.74 on 2026-08-07 to $6.89 on 2026-08-21 while three banks cut targets with ratings held. The 2026-08-28 Oberland closing funds $50M inside 30 days; the October VS-7375… ZURA Zura Bio Limited MEDIUM Q2 print (2026-08-11) added a third tibulizumab indication — polymyalgia rheumatica, NEXUS-PMR Phase 2 by YE2026 — and Wedbush ($22) plus Guggenheim ($20) raised targets on 2026-08-12; the $5.57 close on 2026-08-14 has not paid for it. The… ABCL AbCellera Biologics Inc. LOW Binary resolved positive: ABCL635 Phase 2 hit both primaries on 2026-08-10 (placebo-adjusted −5.3 hot flashes/day, p<0.001), and the stock re-rated to a 52-week-high $11.38 close on 2026-08-14 at RSI 97.4. The company priced $200M of… ABEO Abeona Therapeutics Inc. LOW The 2026-08-13 Q2 print missed both lines — revenue $11.38M vs ~$12.24M, EPS -$0.35 vs -$0.23 — and price has given back 18.4% from the $7.46 high. But treated patients rose to five from three and the QTC network hit its seven-center 2026… ABVX Abivax SA LOW Post-binary single-asset UC biotech that has now lost the $125.00 placement shelf — 2026-08-14 close $118.96 — despite a positive 2026-07-30 pre-NDA FDA interaction. Sell-side sits ~$161.55 average against the tape, the CEO has framed a… AKBA Akebia Therapeutics, Inc. LOW VOICE outcomes win (USRC trial stopped early, June 2026) de-risked Vafseo's dialysis-anemia case, but the tape bled to ~$1.22, only ~48% above the $0.82 low and still fading; the late-July/early-August Q2 print is the binary —… ALMS Alumis Inc. LOW Psoriasis leg is fully told — 2026-08-10 ONWARD3 48-week data (75% PASI 90 / 54% PASI 100) left the stock 16.5% under its $30.30 52-week high. The only re-rating leg left is the undated LUMUS Phase 2b lupus topline, reaffirmed for Q3 2026… AMLX Amylyx Pharmaceuticals, Inc. LOW Single-asset binary, now inside the guided window: Amylyx reaffirmed on 2026-08-06 that Phase 3 LUCIDITY topline for avexitide in post-bariatric hypoglycemia arrives late August or early September 2026. Sell-side marked targets up into it… ANAB AnaptysBio, Inc. LOW The dateless wait acquired a docket: a 2026-07-28 stipulation set post-trial briefing to an Oct 20 Chancery argument, and ANAB has rebuilt from ~$54 (Jul 24) to $58.47 (Aug 14) on no company news. The written opinion deciding Jemperli… ANRO Alto Neuroscience Inc. LOW Precision-psychiatry TRD re-rate broke to new highs on a low-information 2026-08-12 Q2 print (EPS -$0.65 vs -$0.73 est) and two same-week target revisions (BTIG $37 Buy, Wedbush $26 Neutral). The 2026-08-14 close of $32.14 sits 0.5% under… APGE Apogee Therapeutics, Inc. LOW HSR expiry (2026-08-05) and shareholder approval (2026-08-11) cleared the last stated conditions on AbbVie's $135.11 all-cash takeout, so what trades now is terminal merger-arb carry into a company-guided Q3-2026 close — capped at the bid,… ATAI AtaiBeckley Inc. LOW Lilly takeout is now a process, not a story: DEFM14A filed, special meeting 2026-09-08, HSR filed 2026-07-29, close guided Q3 2026. The 2026-08-14 close of $7.26 sits $0.51 over the $6.75 cash leg, so all remaining return is an unread CVR… AVLN Avalyn Pharma Inc. LOW Post-IPO re-rating in an inhaled-antifibrotic single-asset story: the 2026-08-14 close of $39.25 is +118% over the $18.00 April IPO price with RSI(14) at 89.2, yet the MIST Phase 2b FVC readout that sets the value is guided to 2H 2027.… AVTR Avantor, Inc. LOW The post-print re-rating is digesting rather than extending: $13.66 on 2026-08-14 versus $13.59 on 2026-08-07, RSI(14) cooling 77.0 to 69.5, and the 2026-07-30 target cluster of $14–$16 already reached. Management's Q3 guide — about 250 bp… AVTX Avalo Therapeutics, Inc. LOW The July soft catalyst has passed: Q2 landed 2026-08-06 and delivered a schedule — registrational Phase 3 in hidradenitis suppurativa initiating H1 2027 — so the post-LOTUS story now sits in a ~10-month gap with no company-dated clinical… BHC Bausch Health Companies Inc LOW Levered deleveraging/separation stub: $2.41B equity on $20,239M long-term debt principal, with an 87% Bausch + Lomb stake as the main asset. The 2026-07-29 beat-and-raise (adj EPS $1.26 vs $1.04, FY sales guide to $10.790–11.040B) drove… BHVN Biohaven Ltd. LOW Binary-catalyst biotech: the re-rate off the $7.48 Nov-CRL low stalled at ~$16 in early July and drifted to $13.85 on 2026-08-21. The undated 2H-26 RISE3 topline now races a live $350.0M J.P. Morgan ATM (424B5, 2026-05-04) against ~$270.5M… BIOA BioAge Labs, Inc. LOW The ESC venue hypothesis failed: ZEUS is absent from the published ESC 2026 Hot Line programme (Munich, 2026-08-28 to 08-31), so the full dataset that would separate NLRP3 from IL-6 blockade does not land in August and no substitute date… BOLD Boundless Bio, Inc. LOW Merger-arb wrapper, not an oncology stock: the object is a planned $44–48M pre-close cash dividend plus a 3.69% stub in the AATD base-editing NewCo. Week of 2026-08-14 added owners (ADAR1 13G at 8.8%) but no deal documents — still no S-4,… CERS Cerus Corporation LOW Profitability inflection intact — 9th straight positive adjusted-EBITDA quarter (+$3.0M) and a $30M term-loan paydown at the 2026-07-30 Q2 print — but product growth halved to +10% YoY from +24% in Q1 and gross margin fell to 51.4% from… CLPT ClearPoint Neuro, Inc. LOW Picks-and-shovels delivery play on CNS gene therapy: ClearPoint's SmartFlow cannula and MRI navigation are the standard route to the brain for uniQure's AMT-130 Huntington's BLA (soft Q3-2026 window). The June re-rate held near $18.72… CLYM Climb Bio, Inc. LOW Anti-CD19 autoimmune re-rate: budoprutug's 2026-06-11 EHA ITP data (>90% B-cell depletion, n=15) plus $239.2M cash funding into 2H 2028 lifted CLYM to a 52-week high at $16.33 on 2026-08-14. The 2026-09-03 R&D Spotlight (CLYM116 Phase 1… CNTA Centessa Pharmaceuticals plc LOW Closed cash-plus-CVR takeout; nothing trades. Lilly's scheme ($38.00 cash plus a non-transferable CVR of up to $9.00) went effective 2026-06-24, Form 15-12G dated 2026-07-06. New since the last note: ClinicalTrials.gov lists a Phase… CORT Corcept Therapeutics Incorporated LOW Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry… CPIX Cumberland Pharmaceuticals Inc. LOW Deal-arb thesis is now spent: the $100M Apotex asset sale closed 2026-07-01 after a 99.84% shareholder vote on 2026-06-24, so the dated binary that drove the ~3.2x off $1.85 to a $7.36 high is consumed. What remains is a cash-rich clinical… CRL Charles River Laboratories International, Inc. LOW Post-2026-08-05 demand-recovery leg extended to a new 52wk high at the 2026-08-21 close of $295.19 (RSI 86.6, +84.1% over three months) with no rating action since TD Cowen's $300 on 08-10 — price is now inside the $282-$310 target band.… CRNX Crinetics Pharmaceuticals, Inc. LOW Not a narrative any more: the Vertex $85.00/share cash takeout cleared HSR on 2026-08-12, the stockholder vote is 2026-08-28, and closing is guided to early September. At the 2026-08-14 close of $84.70 the gap to terms is $0.30 against… CRVS Corvus Pharmaceuticals, Inc. LOW Calendar still empty until 2027 after the 2026-08-06 push-out (PTCL futility Q1 2027, no data released; SIERRA1 topline Q3 2027), but the tape has recovered: $14.46 close on 2026-08-21 with RSI 62.4 versus $13.92 and RSI 47.5 on… DFTX Definium Therapeutics, Inc. LOW Voyage GAD read out positive on 2026-08-12 — HAM-A 5.4 points over placebo at Week 12, p<0.0001, Cohen's d 0.81 — and eight target actions followed inside seven sessions. Yet the 2026-08-21 close of $44.91 sits under the pre-readout $46.14… DSGN Design Therapeutics, Inc. LOW A new 52-week high of $15.94 printed in August with no company release since the 2026-08-03 Q2 update, which pushed the next hard data to Q1 2027. RSI(14) 73.9 at the $14.99 close (2026-08-21) and +21.9% for the month, into a 30-day… DXCM DexCom, Inc. LOW CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind — Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-$70s still under the 200-EMA and the confirmed July 30 Q2 print is… ESPR Esperion Therapeutics, Inc. LOW Resolved and off the tape. ARCHIMED's take-private closed 2026-07-13 at $3.16 cash plus a non-tradeable CVR of up to $100M; Nasdaq was asked to file Form 25 the same day and reporting duties are being suspended by Form 15. The early-August… FBRX Forte Biosciences, Inc. LOW Deal-spread endgame: HSR expired 2026-08-18 (SC 14D9/A filed 2026-08-19), leaving only the >50% minimum tender before argenx's $77.00 all-cash offer expires 2026-08-26. The 2026-08-21 close of $76.92 leaves $0.08 of gross gap. Upside is… FDMT 4D Molecular Therapeutics, Inc. LOW Wet-AMD one-and-done durability narrative accelerating on the 2026-07-18 PRISM 2-year data (78% injection-burden reduction, 2.7 vs 12.0 projected, n=30) plus a 2026-07-31 Buy initiation at PT $37 and a 2026-08-13 Q2 beat. Price is 5.5% off… FTRE Fortrea Holdings Inc. LOW Post-spin margin-repair narrative is now fully written into sell-side models and no longer into the tape: five target raises through 2026-08-04 (TD Cowen $23) met a slide from $19.17 (7/31) to $17.41 (8/14), surrendering the July… GLUE Monte Rosa Therapeutics, Inc. LOW ZEUS (ziltivekimab, MACE HR 0.99) failed on 2026-07-31 and took GLUE −27.16% to $16.52, its worst session on record, because the hsCRP-to-outcomes link under MRT-8102's ASCVD story is exactly what ZEUS could not demonstrate. Platform,… GTN Gray Media, Inc. LOW August's double catalyst — FCC 2-1 repeal of the 39% ownership cap (2026-08-06) and a Q2 beat-and-raise (2026-08-07) — has stopped extending: the 2026-08-21 close of $4.94 lost the $5.00 handle and sits 18.7% under the $6.07 52-week high.… HELP Cybin Inc. fresh LOW Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a 10.3M-share secondary at $4.85. Both covering shops cut targets in July while holding Buy. No… HIMS Hims & Hers Health, Inc. LOW GLP-1 reaccel gets marked to market on 2026-08-10: guide $680-700M (+25-28%) vs Q1's +4%, street at $698.9M. Since the last note the FTC/CA/UT sued (2026-07-29, N.D. Cal.), BofA cut $37 to $30, and Amazon ($50/mo Medicare GLP-1,… HROW Harrow, Inc. LOW Post-Q2 this is a leverage-and-execution show-me: the reaffirmed $350–365M FY guide needs H2 to roughly double the $114.9M booked in H1, against $292.4M loans payable net and $14.8M equity. The 2026-08-20 IHEEZO comfort data supports the… INBX Inhibrx Biosciences, Inc. LOW Non-dilutive bridge into the 2027-04-14 PDUFA, with one item pulled forward: the 2026-08-13 Q2 release moved the INBRX-106 HNSCC PFS readout into Q3 2026 and dated the CRC registrational FDA meeting to Q4 2026. But the two-week advance… IRWD Ironwood Pharmaceuticals, Inc. LOW Post-print drift: the 2026-08-06 binary resolved with FY26 guidance raised (revenue $460–485M, adjusted EBITDA above $310M) but both reported lines missing consensus, and two weeks on the stock is unchanged at $4.29, 20.4% under the $5.39… IVA Inventiva S.A. LOW Single-asset MASH binary, still dormant: zero company news in the 30 days to 2026-08-23, with the undated Q4 2026 NATiV3 topline carrying the whole equity. RSI(14) firmed to 66.7 at the $4.68 close on no flow, while the $4.40 June offering… JBIO Jade Biosciences, Inc. LOW The post-Q2 revision leg round-tripped: $24.71 on 2026-08-14 back to $21.34 on 2026-08-21, with the 2026-08-11 target raises (Wedbush $47, Jefferies $48 from $40) marking the high rather than starting a leg. The July shelf near $21 is now… KALV KalVista Pharmaceuticals, Inc. LOW Resolved cash takeout, not a live security: Chiesi's $27.00/share acquisition closed 2026-06-11, KALV delisted the same morning, Form 15-12G filed 2026-06-22, and Rule 12g-4 registration termination lands ~2026-09-20. The 2026-06-10 close… KOD Kodiak Sciences Inc LOW Binary-catalyst redemption arc now inside its final month: DAYBREAK wet-AMD one-year topline guided September 2026. Price keeps stepping down through good news — $42.64 (07-17) to $41.35 (08-14) to $38.33 (08-21), -17.5% from the $46.44… KURA Kura Oncology, Inc. LOW The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A… LEGN Legend Biotech Corporation LOW In-vivo CAR-T re-rate has matured into digestion: EHA (6/13) confirmed LB2501's 100% ORR and clean durability, but the 6/17 $226M raise at $29.35 capped the leg and JPM's 7/13 Neutral $35 reinstatement caps the Street. No fresh catalyst… LQDA Liquidia Corporation LOW The prior break level triggered: LQDA closed the week at $68.62 on 2026-08-21, through the $70 July shelf and the 08-13 low close of $72.10, despite six post-print targets at $90–$111. Q2 sales grew +31% QoQ, but the re-rating leg is… MAZE Maze Therapeutics, Inc. LOW APOL1 kidney precision-medicine story intact, but the 2026-08-11 Q2 print emptied 2026 of catalysts: MZE782 PKU topline pushed to 2027 and CKD Phase 2 start to H1 2027, leaving only HORIZON's three 10–15 patient cohorts in… MEDP Medpace Holdings, Inc. LOW Bookings-inflection leg (Q2 awards $795.7M, +28.2% YoY, book-to-bill 1.13x, FY26 guides raised 2026-07-22) is intact on fundamentals but stalled on the tape: the $620.59 high faded to a $578.5 close on 2026-08-14, RSI 45, while the CEO… MNTN MNTN, Inc. LOW Post-IPO CTV adtech re-rating on a profitability crossover: Q2 (2026-08-04) delivered $82.5M revenue +21% YoY, 80% gross margin, $6.7M GAAP net income vs a $26.2M loss, and a $100M buyback. Shares +53.9% in three months into a 91.4 RSI… MRVI Maravai LifeSciences Holdings, Inc. LOW Leg has flipped from operating leverage to mRNA-supplier read-through: Moderna's 2026-08-19 Phase 3 cancer-vaccine data took MRVI +25.8% in one session and to an $8.64 52-week-high close by 2026-08-21 with RSI 79.8 — while FY26 revenue… MYGN Myriad Genetics, Inc. LOW Legacy hereditary-cancer testing house executing a diagnostics pivot; shares +40% off the June $3.99 base as Prolaris+AI launched (May 26) and Precise MRD colorectal/renal was pulled forward to Q3. Structure has repaired but now… NEO NeoGenomics, Inc. LOW Oncology-dx turnaround accelerating — NGS +26%, PTEN IHC CDx (first FDA IHC companion dx in prostate, paired to AZ's TRUQAP) launched Jul 9, and TD Cowen $14→$19 / BofA $11→$16 on Jul 13 lifted consensus to ~$15.67, back above spot. But Q2… NUVL Nuvalent, Inc. LOW Closed, not pending: GSK completed the $124 all-cash acquisition on 2026-07-15 after 91.3% of shares were tendered by the 2026-07-14 expiry; trading was suspended 2026-07-15 and Form 25 delisting requested. No US-listed NUVL equity remains… OABI OmniAb, Inc. LOW Milestone-and-royalty flywheel turned visible: Q2 revenue $13.415M vs $4.693M consensus (2026-08-06) plus a Lilly ion-channel deal worth up to $370M in milestones (2026-08-17) took closes from $1.96 to $4.33 in thirteen sessions. RSI(14)… ODD ODDITY Tech Ltd. LOW Compounder narrative is dead (Q1 revenue -26%, first orders -50%) and the drift continued on no news at all: $14.12 on 2026-08-07 to $13.22 on 2026-08-21, now sitting on the $13 shelf. The 2026-09-09 pre-market Q2 print is the only dated… OGN Organon & Co. LOW Deal-pinned arb, now purely regulatory: the $14.00 all-cash Sun Pharma offer was approved by holders 2026-07-23 and the 2026-08-21 close of $13.75 leaves $0.25, ~1.8% gross, into a stated early-2027 close. Upside is capped by contract; a… OMER Omeros Corporation LOW Post-print launch-ramp narrative still accelerating on fundamentals — Q2 net sales $28.5M vs $12.7M consensus (2026-08-12), NTAP effective 2026-10-01 — but the shares added 12.1% from the 2026-08-14 close of $17.19 to $19.27 on 2026-08-21… QURE uniQure N.V. LOW FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA — the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on… RARE Ultragenyx Pharmaceutical Inc. LOW The +50% June reset rally round-tripped from ~$33.46 to $28.62 (2026-07-21), parking price back on the breakout shelf ahead of two binary FDA decisions: DTX401 (GSD Ia) PDUFA Aug 23 and UX111 (Sanfilippo A) PDUFA Sep 19. The July 30 Q2… RLYB Rallybio Corporation LOW No new filing since the 2026-08-06 10-Q: as of 2026-08-23 the 2026-07-15 S-4 is still not effective, with no record date or meeting date set. The 2026-08-21 close of $16.83 sits ~7% above the ~$15.68/share implied by the S-4's $83.2M Net… SGMT Sagimet Biosciences Inc. Series A LOW April denifanstat/acne breakout round-tripped to the $6.00 Series A offering floor; SGMT bases near $7 (last close $7.06, 2026-06-26) with no trend. Dermatology pivot (China NMPA acne NDA accepted Dec 2025, US IND due mid-2026) is real but… SLS SELLAS Life Sciences Group, Inc. LOW Cancer-vaccine sector re-rate after Merck/Moderna's 2026-08-19 Phase 3 win carried SLS to a 52-week closing high of $15.46 on 2026-08-21 (+15.4% on the session, RSI 78.7) with no SELLAS data of its own; REGAL's last published count is… SMMT Summit Therapeutics Inc. LOW Two positive headlines on 2026-08-12 — Akeso's third China approval and a Leerink upgrade — left the stock lower: the 2026-08-21 close of $13.16 sits under the 2026-08-14 close and just above the $12.55 52-week low. The dated binary is the… SPRY ARS Pharmaceuticals, Inc. LOW Single-product epinephrine name whose one catalyst — a July no-prior-auth formulary add for neffy — came and went unpaid; the stock has since broken its old $6.66 52-week low to fresh lows near $6. The neffy ramp is real but the access… STRO Sutro Biopharma, Inc. LOW Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June… TDOC Teladoc Health, Inc. LOW The Walmart/insurance-pivot re-rating broke at the 2026-07-29 Q2 print: revenue -4% YoY, BetterHelp -12%, FY26 revenue guide cut ~5% at the midpoint. What remains is $774M cash and a maintained $130-170M FCF guide against a shrinking top… TECH Bio-Techne Corp LOW Closed merger-arb pinned $0.60 under Merck KGaA's $73.00 all-cash bid — 2026-08-14 close $72.40, also the 52-week high. Q4 printed 08-12 with no call and no FY27 guidance; Wells Fargo folded to a $73 target on 08-13. Coverage is fully… TENX Tenax Therapeutics, Inc. LOW Phase 3 binary resolved negative: LEVEL missed its primary (6MWD +3.5m, p=0.63) and key secondary on 2026-08-10; four desks cut within 24h and the target band went from $27–$50 to $4–$5. Narrative is dead. What is left is a balance-sheet… TGTX TG Therapeutics, Inc. LOW The catalyst leg is spent; what is left is whether the $46–48 shelf holds through a two-month news vacuum into year-end subcutaneous Phase 3 topline. TSHA Taysha Gene Therapies, Inc. LOW Clinical binary printed clean (2026-06-22: 100% milestone response N=12, zero treatment-related SAEs) but the next catalyst slipped to H1 2027 — pivotal six-month interim AND FDA BLA-pathway feedback both guided to the first half of next… VERU Veru Inc. LOW The Novo squeeze is fully round-tripped and the funding answer arrived on 2026-07-02: a $21.8M at-the-market program via Oppenheimer/Canaccord. At $2.42 (07-15) that is ~9M shares against ~16M outstanding — the company will now sell stock… VIR Vir Biotechnology, Inc. LOW Q2 (2026-08-05) printed $238.9M revenue and $0.47 diluted EPS on Astellas upfront recognition — an accounting swing, and the tape read it as one: $9.24 on 2026-08-14, still under the $10.36 Astellas equity strike, with Morgan Stanley and… VKTX Viking Therapeutics, Inc. LOW The ~$34 line from July gave way — $33.19 close on 2026-08-14, -21.2% from the $42.13 high. Only company-guided 2026 event left is the VK2735 maintenance-dose readout (3Q26); pivotal VANQUISH topline is 2027. JPMorgan cut its target to $65… WING Wingstop Inc. LOW Two analyst target cuts in ten days (Wells Fargo to $170, DA Davidson to $200) into the 2026-07-29 Q2 print signal de-risking ahead of the H2 comp-turn binary; a ~50% relief bounce off the $116.35 low is unproven, and the print — not… XENE Xenon Pharmaceuticals Inc. LOW Q2 (2026-08-06) cleared the last procedural gate — FDA pre-NDA meeting completed, azetukalner FOS NDA still guided to Q3 2026, cash $1,245.1M — and the stock still closed 2026-08-14 at $62.35, 12.1% below the $70.96 July high with RSI… XTLB XTL Biopharmaceuticals Ltd. LOW Delisting binary fully resolved — Nasdaq confirmed compliance 2026-07-20 — and the pivot pop has bled off: no dated company release since, ADS $2.94 (2026-07-25) → $2.79 (2026-08-14), RSI 44.4. Event narrative is saturated; the next leg… ZVRA Zevra Therapeutics, Inc. LOW The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now… ALVO Alvotech fresh NONE